Acorda Therapeutics Inc. (ACOR) announced Monday morning that data from a Phase 2 study of AMPYRA Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.
Acorda Therapeutics gapped up sharply Monday and is now trading higher by 2.73 at $34.25. The stock has risen above a 2 1/2 week range and has set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.